Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive pulmonary disease (COPD). It contains an inhaled corticosteroid called ...

Symbicort is a type of inhaled long-term asthma medication. It combines two active ingredients in one inhaler: a corticosteroid called budesonide and a bronchodilator called formoterol.

Symbicort was first FDA-approved in 2006 as ... a long-acting beta2-agonist bronchodilator with a fast action, in a single inhaler. A Viatris spokesperson said: "Viatris obviously disagrees ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

AstraZeneca’s Symbicort inhaler accounts for most of its inhalation portfolio revenue, projected by GlobalData to generate a total $2.5bn in 2024. Meanwhile GSK's lead inhalers include Trelegy ...